The effect of vortioxetine on overall patient functioning in patients with major depressive disorder

The objectives of this meta‐analysis of data from randomized, placebo‐controlled studies were to assess the effect of vortioxetine on overall functioning (primary) and functional remission (secondary) using the Sheehan Disability Scale (SDS) in adults with major depressive disorder (MDD).

[1]  JAMA. , 2019, JAMA.

[2]  M. Thase,et al.  A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults , 2016, European Neuropsychopharmacology.

[3]  D. Sheehan,et al.  Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors , 2015, Human psychopharmacology.

[4]  M. Trivedi,et al.  A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. , 2015, The Journal of clinical psychiatry.

[5]  M. Trivedi,et al.  A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. , 2015, The Journal of clinical psychiatry.

[6]  A. Heinemann,et al.  Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial. , 2015, JAMA psychiatry.

[7]  Ronald C Kessler,et al.  The economic burden of adults with major depressive disorder in the United States (2005 and 2010). , 2015, The Journal of clinical psychiatry.

[8]  S. Montgomery,et al.  Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study , 2015, Current medical research and opinion.

[9]  M. Trivedi,et al.  A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD , 2015, Psychopharmacology.

[10]  S. Kennedy,et al.  The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial , 2014, Psychiatry Research.

[11]  S. Montgomery,et al.  A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine , 2014, Human psychopharmacology.

[12]  C. Gommoll,et al.  Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials , 2014, International clinical psychopharmacology.

[13]  R. McIntyre,et al.  A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults , 2014, The international journal of neuropsychopharmacology.

[14]  C. Olsen,et al.  Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder , 2014, International clinical psychopharmacology.

[15]  J. Endicott,et al.  Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder , 2014, CNS Spectrums.

[16]  D. Sheehan,et al.  A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder , 2013, Journal of clinical psychopharmacology.

[17]  A. Gnanasakthy,et al.  Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder , 2014, Neuropsychiatric disease and treatment.

[18]  S. Montgomery,et al.  The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study , 2013, International clinical psychopharmacology.

[19]  G. Freedman,et al.  Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 , 2013, PLoS medicine.

[20]  C. Gommoll,et al.  Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. , 2013, The Journal of clinical psychiatry.

[21]  M. Thase,et al.  A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. , 2013, The international journal of neuropsychopharmacology.

[22]  Yinzhong Chen,et al.  A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder , 2013, Current medical research and opinion.

[23]  V. Pérez,et al.  Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. , 2012, Journal of affective disorders.

[24]  D. Sheehan,et al.  Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies , 2012, International clinical psychopharmacology.

[25]  M. Thase,et al.  A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. , 2012, The Journal of clinical psychiatry.

[26]  D. Baldwin,et al.  A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD) , 2012, European Neuropsychopharmacology.

[27]  Cornelius Katona,et al.  A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder , 2012, International clinical psychopharmacology.

[28]  M. Zimmerman,et al.  Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? , 2012, The Journal of clinical psychiatry.

[29]  C. Bundgaard,et al.  Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder , 2012, Journal of Pharmacology and Experimental Therapeutics.

[30]  M. Thase,et al.  Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol , 2012, Human psychopharmacology.

[31]  C. Soares,et al.  Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis , 2012, International clinical psychopharmacology.

[32]  B. Dunlop,et al.  Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo , 2011, Journal of clinical psychopharmacology.

[33]  R. Lam,et al.  Clinical effectiveness: the importance of psychosocial functioning outcomes. , 2011, Journal of affective disorders.

[34]  V. Pérez,et al.  A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder , 2011, The international journal of neuropsychopharmacology.

[35]  Thomas Ruhland,et al.  Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. , 2011, Journal of medicinal chemistry.

[36]  D. Sheehan,et al.  Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale , 2011, International clinical psychopharmacology.

[37]  J. Modell,et al.  Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR , 2010, Journal of psychopharmacology.

[38]  S. Stahl,et al.  Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial , 2010, Journal of clinical psychopharmacology.

[39]  I. Gilaberte,et al.  Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study , 2010, European Psychiatry.

[40]  M. Thase,et al.  Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. , 2009, The Journal of clinical psychiatry.

[41]  R. Lennox,et al.  Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning , 2009, International clinical psychopharmacology.

[42]  Patrick E. McKnight,et al.  The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. , 2009, Clinical psychology review.

[43]  M. Frye,et al.  The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder , 2009, Psychiatry Research.

[44]  M. Posternak,et al.  Remission in depressed outpatients: more than just symptom resolution? , 2008, Journal of psychiatric research.

[45]  L. Judd,et al.  Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. , 2008, Journal of affective disorders.

[46]  D. Sheehan,et al.  Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale , 2008, International clinical psychopharmacology.

[47]  Maurizio Fava,et al.  Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. , 2008, The American journal of psychiatry.

[48]  Vikram Patel,et al.  Depression, chronic diseases, and decrements in health: results from the World Health Surveys , 2007, The Lancet.

[49]  Mark D. Miller,et al.  Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study , 2007, British Journal of Psychiatry.

[50]  M. Posternak,et al.  Discordance between self-reported symptom severity and psychosocial functioning ratings in depressed outpatients: Implications for how remission from depression should be defined , 2006, Psychiatry Research.

[51]  J. Owens,et al.  Patients with attention-deficit/hyperactivity disorder without observed apneic episodes in sleep or daytime sleepiness have normal sleep on polysomnography. , 2005, Sleep.

[52]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[53]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[54]  Jae-Chang Jung,et al.  Mitogen-Activated Protein Kinase Inhibition in Traumatic Brain Injury: In Vitro and In Vivo Effects , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  D. Sheehan,et al.  The measurement of disability , 1996, International clinical psychopharmacology.

[56]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[57]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[58]  F. Artigas,et al.  Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. , 2015, Pharmacology & therapeutics.

[59]  P. Luyten,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2015 .

[60]  D. Kajdasz,et al.  The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. , 2008, Primary care companion to the Journal of clinical psychiatry.

[61]  D. Sheehan,et al.  The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. , 2008, Current medical research and opinion.

[62]  A. Castaigne,et al.  EFFICACY AND SAFETY OF AN ORAL FIXED LOW-DOSE PERINDOPRIL 2 MGDNDAPAMIDE 0.625 MG COMBINATION: STUDY IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSION A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED , 1999 .

[63]  R. Entsuah.  Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. , 1996, Journal of biopharmaceutical statistics.